v3.26.1
Note 16 - Geographic and Segment Information - Profit and Loss Information by Reportable Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Total revenue $ 90 $ 27 $ 105 $ 108
Cost of revenue 36 0 36 20
Research and development 3,471 3,514 3,800 4,995
Depreciation 353 366 708 770
Total stock-based compensation 1,040 1,367 2,352 [1] 3,314
Segment loss from operations (5,347) (5,864) (7,408) (9,940)
Research and Development [Member]        
Depreciation 336 337 674 675
Total stock-based compensation 526 600 1,240 [1] 1,546
General and Administrative [Member]        
Depreciation 17 29 34 95
Total stock-based compensation 514 767 1,112 [1] 1,768
Operating Segments [Member]        
Total revenue 90 27 105 108
Cost of revenue 36 0 36 20
Segment loss from operations (5,347) (5,864) (7,408) (9,940)
Operating Segments [Member] | Research and Development [Member]        
Facilities 393 386 784 805
Depreciation 336 337 674 675
Manufacturing 522 187 155 270
Research 1 2 10 7
Equipment 24 14 84 28
Maintenance 32 32 49 64
Information technology 76 54 143 119
Personnel 2,188 2,100 4,211 4,260
Total stock-based compensation 526 600 1,240 1,546
Grant revenue as a reduction of research and development expense (1,864) (2,058) (5,914) (6,225)
Other segment items - Research and development [2] 16 79 33 104
Operating Segments [Member] | General and Administrative [Member]        
Facilities 30 31 63 61
Depreciation 17 29 34 95
Information technology 40 47 62 96
Total stock-based compensation 514 767 1,112 1,768
Grant revenue as a reduction of research and development expense (93) (65) (329) (228)
Insurance 177 181 328 362
Legal 144 175 195 323
Finance and accounting 155 220 488 530
Public and investor relations 109 119 202 230
Personnel 779 788 1,417 1,620
Other segment items - General and administrative [3] 58 85 105 176
Operating Segments [Member] | CNM-Au8, Amyotrophic Lateral Sclerosis [Member]        
Research and development 712 1,468 1,536 2,811
Operating Segments [Member] | CNM-Au8, Multiple Sclerosis [Member]        
Research and development 37 164 107 189
Operating Segments [Member] | CNM-Au8, Regulatory Activities [Member]        
Research and development 371 130 567 260
Operating Segments [Member] | General, Preclinical, Nonclinical [Member]        
Research and development 101 19 121 82
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]        
Segment loss from operations $ 0 $ 0 $ 0 $ 0
[1] Excludes $1.1 million of stock options issued to pay deferred employee compensation recorded in accrued liabilities.
[2] Includes expenses for travel, meals, dues, subscriptions, continuing education, and other miscellaneous expenses.
[3] Includes expenses for travel, meals, dues, subscriptions, continuing education, lobbying, banking fees, postage, and other office and miscellaneous expenses.